Medical oncology considerations in patients with metastatic neuroendocrine carcinomas.
Kvols
L
L
Mallinckrodt Medical, Inc., St Louis, MO 63134.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008495:Medical Oncology; D018358:Neuroendocrine Tumors / Q000378:metabolism / Q000503:physiopathology* / Q000556:secondary* / Q000628:therapy; D015282:Octreotide / Q000627:therapeutic use; D012074:Remission Induction; D015996:Survival Rate
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D015282:Octreotide